Medicine and Dentistry
Neoplasm
100%
Prostate Cancer
71%
Overall Survival
45%
Pancreas Adenocarcinoma
33%
Castration Resistant Prostate Cancer
31%
Progression Free Survival
30%
Enzalutamide
25%
Biological Marker
25%
Radiation Therapy
25%
Prostate Specific Antigen
22%
Disease
20%
Head and Neck Squamous Cell Carcinoma
20%
Colorectal Cancer
20%
Immunotherapy
19%
Pancreas Cancer
19%
Surgery
19%
Positron Emission Tomography-Computed Tomography
18%
Malignant Neoplasm
18%
Prostatectomy
18%
Head and Neck Cancer
17%
Programmed Death-Ligand 1
16%
Metastatic Carcinoma
16%
Nodular Melanoma
15%
T Cell
15%
Abiraterone
15%
Fluorodeoxyglucose F 18
15%
Androgen Receptor
14%
Clinical Trial
14%
Chemoradiotherapy
14%
Positron Emission Tomography
13%
Nivolumab
13%
Hazard Ratio
12%
DNA Mismatch Repair
12%
Programmed Death 1 Ligand 1
12%
Cancer
12%
Tumor Cell
11%
Wart Virus
10%
Ipilimumab
10%
Phase II Trials
10%
Recurrent Disease
10%
Gene Mutation
9%
Arm
9%
Immune Response
9%
Dysplasia
9%
DNA Repair
9%
Gleason Score
9%
Treatment Response
9%
Non Small Cell Lung Cancer
9%
Homologous Recombination
8%
Promoter Region
8%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
69%
Prostate Cancer
61%
Castration Resistant Prostate Cancer
52%
Androgen
43%
Overall Survival
39%
Enzalutamide
37%
Prostate Specific Antigen
34%
Progression Free Survival
29%
Malignant Neoplasm
26%
Abiraterone
25%
Androgen Receptor
20%
Pancreas Adenocarcinoma
20%
Biological Marker
18%
Pancreas Cancer
16%
Clinical Trial
16%
Disease
16%
Chemotherapy
15%
Chemoradiation Therapy
14%
Phase II Trials
11%
CD8 Antigen
11%
Head and Neck Squamous Cell Carcinoma
10%
Head and Neck Cancer
10%
Fluorodeoxyglucose F 18
10%
Gleason Score
9%
Irinotecan
9%
Colorectal Cancer
9%
Capecitabine
9%
Human Papillomavirus
8%
Cancer Staging
8%
Docetaxel
8%
Nivolumab
7%
Mouse
7%
Programmed Death 1 Ligand 1
7%
Tumor Growth
7%
Pharmacodynamics
7%
Cetuximab
6%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
6%
Non Small Cell Lung Cancer
6%
Vaccination Policy
6%
Placebo
6%
Human Papillomavirus Type 16
6%
Immunotherapy
6%
Gemcitabine
6%
Paclitaxel
6%
Radiopharmaceutical Agent
6%
Epidermal Growth Factor Receptor
6%
Clinical Study
5%
Fox
5%
Alkaline Phosphatase
5%
Cisplatin
5%
Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
38%
Overall Survival
36%
Tumor
35%
Enzalutamide
33%
Colorectal Cancer
26%
Abiraterone
25%
Bipolar Androgen Therapy
24%
Androgen Deprivation Therapy
20%
Mismatch Repair
19%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
18%
Progression-free Survival
18%
Prostate-specific Antigen
18%
Programmed Death-ligand 1 (PD-L1)
18%
Pancreatic Ductal Adenocarcinoma
18%
Nivolumab
17%
Pancreatic Adenocarcinoma
17%
Phase II Trial
16%
High Risk
16%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
15%
Recurrent Prostate Cancer
13%
Confidence Interval
13%
Phase II Study
13%
Prostate Cancer
13%
Neoadjuvant
12%
Castration-resistant Prostate Cancer
11%
Radical Prostatectomy
11%
Clinical Outcomes
11%
Oligometastatic Prostate Cancer
10%
Stereotactic Ablative Radiotherapy
10%
Response Predictors
10%
Hazard Ratio
10%
Head-and-neck Cancer
9%
Pancreatic Cancer
9%
Metastatic Pancreatic Ductal Adenocarcinoma
9%
Median Overall Survival
9%
Chemoradiation
9%
Pathologic
9%
Localized Prostate Cancer
8%
Neoadjuvant Therapy
8%
Germ Cells
8%
PD-1 Blockade
8%
Metastasis
8%
Tumor Cells
8%
Colon Cancer
7%
Anti-PD-1 Therapy
7%
Tumor Microenvironment
7%
Response Rate
7%
Docetaxel
7%
High-risk Human Papillomavirus (HR-HPV)
7%
Positron Emission Tomography-computed Tomography (PET-CT)
7%
